Entheon Biomedical (XCNQ:ENBI) Gross-Profit-to-Asset % : 0.00% (As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Entheon Biomedical's annualized Gross Profit for the quarter that ended in Feb. 2024 was C$0.00 Mil. Entheon Biomedical's average Total Assets over the quarter that ended in Feb. 2024 was C$0.35 Mil. Therefore, Entheon Biomedical's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2024 was 0.00%.

Entheon Biomedical Gross-Profit-to-Asset % Historical Data

The historical data trend for Entheon Biomedical's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Gross-Profit-to-Asset % Chart

Entheon Biomedical Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Nov21

Nov22

Nov23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

0.15

3.54

42.74

Entheon Biomedical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															66.67	83.53	-	-	-

Competitive Comparison of Entheon Biomedical's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Entheon Biomedical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entheon Biomedical's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entheon Biomedical's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Entheon Biomedical's Gross-Profit-to-Asset % falls into.

Entheon Biomedical Gross-Profit-to-Asset % Calculation

Entheon Biomedical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Nov. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Nov. 2023 )	/	( (Total Assets (A: Nov. 2022 )	+	Total Assets (A: Nov. 2023 ))	/ count )
	=	0.25	/	( (0.769	+	0.401)	/ 2 )
	=	0.25	/	0.585
	=	42.74 %

Entheon Biomedical's annualized Gross-Profit-to-Asset % for the quarter that ended in Feb. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Feb. 2024 )	/	( (Total Assets (Q: Nov. 2023 )	+	Total Assets (Q: Feb. 2024 ))	/ count )
	=	0	/	( (0.401	+	0.292)	/ 2 )
	=	0	/	0.3465
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Feb. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Entheon Biomedical Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Entheon Biomedical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Entheon Biomedical (XCNQ:ENBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ENTBF:USA 1XU1:Germany

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.entheonbiomedical.com

Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.

Executives

Brian Jahns

Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines